Denisse Castro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/158268/publications.pdf

Version: 2024-02-01

24 100 4
papers citations h-index

28 28 28 148 all docs docs citations times ranked citing authors

1474206

9

g-index

#	Article	IF	CITATIONS
1	An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leukemia and Lymphoma, 2022, 63, 315-325.	1.3	4
2	Primary cutaneous Epsteinâ€Barr virusâ€positive Bâ€cell lymphoid proliferation with features of diffuse large Bâ€cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. International Journal of Dermatology, 2022, , .	1.0	0
3	Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study. Cancer Management and Research, 2022, Volume 14, 1075-1085.	1.9	6
4	Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leukemia Research, 2021, 102, 106513.	0.8	1
5	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Global Oncology, 2021, 7, 1151-1166.	1.8	15
6	A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma. Blood, 2021, 138, 1404-1404.	1.4	0
7	Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell. Blood, 2021, 138, 2520-2520.	1.4	O
8	Clinico-Epidemiological Features of Elderly Patients with Peripheral T-Cell Lymphoma Not Otherwise Specified: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood, 2021, 138, 2468-2468.	1.4	0
9	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 637-646.	0.4	3
10	EBVâ€positive diffuse large Bâ€cell lymphoma, not otherwise specified: 2020 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2020, 95, 435-445.	4.1	35
11	High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e551-e557.	0.4	9
12	The neutrophilâ€lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. British Journal of Haematology, 2019, 184, 650-653.	2.5	14
13	Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL). Blood, 2019, 134, 4045-4045.	1.4	2
14	Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL). Blood, 2019, 134, 4047-4047.	1.4	3
15	A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL). Blood, 2019, 134, 4121-4121.	1.4	0
16	Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte) Tj ETQq Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival. Blood, 2019, 134, 1613-1613.	0 0 0 rgB1 1.4	「/Overlock 10 O
17	The Impact on Survival of EBV Positive Diffuse Large B- Cell Lymphoma, Not Otherwise Specified in Young Adults. Blood, 2018, 132, 5407-5407.	1.4	1
18	The Neutrophil-to-Lymphocyte Ratio Is Prognostic in Patients with Diffuse Large B-Cell Lymphoma: A Study from the Latin American Group of Lymphomas (GELL). Blood, 2018, 132, 2987-2987.	1.4	0

#	Article	IF	CITATIONS
19	Validation of the Nccn-Ipi for Diffuse Large B-Cell Lymphoma in Latin American Patients: A Study from the Latin-American Group of Lymphomas (GELL). Blood, 2018, 132, 5395-5395.	1.4	O
20	RDW Is a Prognostic Marker for Patients with Aggressive Peripheral T-Cell Lymphoma. Blood, 2018, 132, 5364-5364.	1.4	0
21	The NCCN-IPI Score Is Prognostic of Survival in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified. Blood, 2018, 132, 5363-5363.	1.4	0
22	Clinical Characteristics and Survival in Patients with EBV Positive Diffuse Large B- Cell Lymphoma, Not Otherwise Specified: Report of 60 Cases. Blood, 2018, 132, 2986-2986.	1.4	0
23	Markers of inflammation as prognostic factors for survival in peripheral T-cell lymphoma in Peru. Annals of Oncology, 2017, 28, xi13.	1.2	0
24	The Prognostic Value of the Neutrophil to Lymphocyte Ratio in 209 Patients with Peripheral T-Cell Lymphoma. Blood, 2014, 124, 1675-1675.	1.4	0